


CLAIMS

1. A compound of the formula



wherein R¹ is fluoro;

s is two;


R² is (C₃-C₆)cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C₁-C₄)alkyl, hydroxy, (C₁-C₆)alkoxy, and (C₁-C₆)alkyl-(C=O)-O-;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein R² is optionally substituted (C₃-C₆)cycloalkyl.


3. A compound according to claim 2 wherein R² is optionally substituted cyclopropyl or cyclobutyl.

4. A compound according to claim 2, wherein the compound has the formula



Ia

5. A compound according to claim 2, wherein the compound has the formula



6. A compound according to claim 1, wherein R² is (C₃-C₆)cycloalkyl.
7. A compound according to claim 2, wherein R² is (C₃-C₆)cycloalkyl substituted with one or two (C₁-C₃)alkyl.
- 5 8. A compound according to claim 2, wherein R² is (C₃-C₆)cycloalkyl substituted with one or two methyl groups.
9. A compound according to claim 2, wherein R² is (C₃-C₆)cycloalkyl substituted with one (C₁-C₃)alkyl.
- 10 10. A compound according to claim 2, wherein R² is (C₃-C₆)cycloalkyl substituted with one methyl, ethyl or propyl group.
11. A compound according to claim 2, wherein said compound is selected from the group consisting of:
- 3-Cyclobutyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine;
- 6-[4-(2,4-Difluoro-phenyl)-oxazol-5-yl]-3-(1-methyl-cyclopropyl)-[1,2,4]triazolo[4,3-
- 15 a]pyridine;
- 6-[4-(2,5-Difluoro-phenyl)-oxazol-5-yl]-3-(1-methyl-cyclopropyl)-[1,2,4]triazolo[4,3-a]pyridine;
- 3-Cyclopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine; and
- 3-Cyclopropyl-6-[4-(2,4-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine.
- 20 12. A method of treating an MAP kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 1.
13. A method of treating a p38 kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound
- 25 according to claim 1.
14. A method for treating a condition selected from the group consisting of arthritis, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty

arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis shock in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1 effective in treating such a condition.

10 15. A pharmaceutical composition for the treatment of a condition selected from the group consisting of arthritis, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke,
15 neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema,
20 contact dermatitis, psoriasis, sunburn, and conjunctivitis shock in a mammal, including a human, comprising an amount of a compound of claim 1 effective in such treatment and a pharmaceutically acceptable carrier.

 16. A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of MAP kinase in a mammal, including a human, comprising an
25 amount of a compound of claim 1 effective in such treatment and a pharmaceutically acceptable carrier.

 17. A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of p38 kinase in a mammal, including a human, comprising an
30 amount of a compound of claim 1 effective in such treatment and a pharmaceutically acceptable carrier.